The present invention relates to Tapentadol Hydrochloride in the polymorphic crystalline Form B, which is substantially free of polymorphic Form A as well as essentially free of low alkyl carboxylic acids or esters of such acids. Furthermore, the present invention provides a process to produce this polymorphic Form B substantially free of Form A and its preparation and use for pharmaceutical compositions. This process as well as the specific crystalline form is uncommon, improved and industrially advantageous. Furthermore, the invention relates to pharmaceutical compositions and uses thereof.
本发明涉及Tapentadol Hydrochloride的多晶形式B,其基本上不含多晶形式A以及基本上不含低烷基
羧酸或其
酯类。此外,本发明提供了制备此多晶形式B的方法,基本上不含形式A及其用于制备药物组成物的制备和使用。这种方法以及特定的晶体形式是不常见的,改进的和工业上有利的。此外,本发明涉及药物组成物和其用途。